Back to search

Article

Metabolic Effects of Switching from TAF/FTC/RPV to BIC/TAF/FTC in Real-World Clinical Setting

2026-02-10

Abstract excerpt

<title>Abstract</title> <p>Background As people living with HIV (PWH) age, the prevalence of comorbidities such as cardiovascular disease, diabetes, and dyslipidemia is increasing, leading to greater polypharmacy. Lifelong antiretroviral therapy (ART) therefore requires regimens that are not only virologically effective and well tolerated, with a high genetic barrier and minimal drug–drug interactions, but also...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9e05d736-95f3-5a72-8fb9-64f1cdcfda2a
DOI
10.21203/rs.3.rs-8483460/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Metabolic Effects of Switching from TAF/FTC/RPV to BIC/TAF/FTC in Real-World Clinical SettingDOI 10.21203/rs.3.rs-8483460/v1
Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.Semantic proximity
Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.Semantic proximity
Raltegravir 1200 mg Once Daily as Maintenance Therapy in Virologically Suppressed HIV-1 Infected Adults : QDISS Open-Label TrialSemantic proximity
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.Semantic proximity
Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity
A Critical Review of the Biochemical Mechanisms and Epigenetic Modifications in HIV- and Antiretroviral-Induced Metabolic SyndromeSemantic proximity
Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity
Projected burden of hypertension-associated cardiovascular disease in people living with HIV versus HIV-negative adults in EswatiniSemantic proximity
Evaluating Nirmatrelvir-Ritonavir (Paxlovid®) in Outpatient COVID-19 Treatment: Safety, Tolerability, and Adherence Insights from Primary Healthcare ClinicsSemantic proximity
Prevalence of Selected Cardiometabolic Risk Factors in The Global ART-Naïve HIV Infected Population: A Protocol for a Systematic Review and Meta-AnalysisSemantic proximity
HIV: how to manage low-level viraemia in people living with HIVSemantic proximity
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz+lamivudine+tenofovir disoproxil among HIV-1 patients newly starting treatment in ChinaSemantic proximity
Select a neighboring publication to make it the new centre.